Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML
This is a randomized, multi-center, double-blind, placebo-controlled study designed to evaluate the efficacy of crenolanib administered following salvage chemotherapy, consolidation chemotherapy, post bone marrow transplantation and as maintenance in relapsed/refractory AML subjects with FLT3 activating mutation.
Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
DRUG: Crenolanib|DRUG: Cytarabine|DRUG: Mitoxantrone|DRUG: Placebo Oral Tablet|DRUG: Fludarabine|DRUG: Idarubicin|DRUG: G-CSF
Event-free survival (EFS), 3 years
Overall Survival, 3 years|Relapse-free Survival (RFS), 3 years|Complete remission rate (CR), 3 years|MRD negative complete remission rate, 3 years
This is a randomized, multi-center, double-blind, placebo-controlled study designed to evaluate the efficacy of crenolanib administered following salvage chemotherapy, consolidation chemotherapy, post bone marrow transplantation and as maintenance in relapsed/refractory AML subjects with FLT3 activating mutation.